Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Anti-GPC3 Chimeric T Cells for Subjects With GPC3-Positive Advanced Hepatocellular Carcinoma

NCT03084380 is registered in ClinicalTrials.gov with Xinqiao Hospital of Chongqing as lead sponsor.

NCT NCT03084380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03084380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Anti-GPC3 Chimeric T Cells for Subjects With GPC3-Positive Advanced Hepatocellular Carcinoma
Lead sponsor
Xinqiao Hospital of Chongqing
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 1, 2017
Completion date
May 31, 2020
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma